Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Summary

The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.

Timeline

Start

2008-04

Primary completion

2010-03

Completion

2010-03

Outcome

Missed primary endpoint

registry Reslizumab 3 mg/kg vs Placebo; p = 0.0541; Adjusted mean difference -0.38 (95% CI -0.76 to 0.01); ANCOVA NCT00587288 ↗

Publications

• Background Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32. doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18.

Drugs

Indications